Company Performance Metrics
- Thomas E. Shenk: Founder
- Lillian Chiang: CEO, Co-Founder & President
Evrys Bio was founded on breakthrough discoveries made at Princeton University. Whereas immuno-oncology drugs engage the patient’s immune system to fight cancer, Evrys Bio antivirals engage the cell’s intrinsic immunity to defend against infection. Evrys Bio’s vision is to develop first-in-class antivirals that are safe, address the problem of
acquired drug-resistance, and provide unique broad-spectrum treatment options. This will transform the practice of medicine by addressing the infectious disease condition holistically as opposed to targeting a specific virus-type.